Xaira reports an AI-designed antibody lead in seven weeks
Xaira reports a preclinical antibody lead seven weeks after DNA synthesis, with target-site selection and reagent preparation completed beforehand.
Xaira's October 2 report follows an oncology antibody through the laboratory: 182 designs yielded 25 initial hits, 18 confirmed binders and nine well-resolved binding measurements.
One selected molecule became a preclinical lead. [1]
The seven-week clock began after the target site and reagents were ready; it included further optimization for binding to a surrogate species. These are selected company case studies, with systematic assessment still to come. [1]
Binding is only the beginning. Xaira's earlier methods explanation separates attaching to a purified protein from recognizing its relevant form on cells and changing its activity. A promising molecule must also remain soluble and stable, avoid unwanted binding elsewhere, and limit the risk of provoking an immune response. Some desirable properties compete: changing a sequence to look more human can compromise others. Laboratory measurements help researchers navigate those trade-offs, but none alone establishes that an antibody will become a useful medicine. [2]
When assessing AI drug discovery, ask how many designs survive each experimental test and what preparation was excluded from the clock. That makes a development claim easier to judge than a count of molecules generated.
Take it further
Examine what survived the laboratory tests Public report; no account or deadline. Examine Figure 1 and the work preceding the clock.
Sources & details 2 sources
Discuss in your voice app
Take the reporting, visual explanations and original sources into a conversation. Copy the brief, paste it into your preferred assistant, then start its voice mode.
Paste the brief into your voice app to discuss this reporting.Revised 4 October 2026. Reporting and visuals refined. Original source dates and prior checks retained.
Reporting sources
- Xaira — October 2 experimental case studies
October 2, 2026. XA-1 counts and timing, Figure 1 and experimental prerequisites; selected programmes, broader assessment pending.
- Xaira — what an antibody must do beyond binding
June 29, 2026 background: biological function, developability and imperfect immunogenicity proxies. Contextual methods, checked October 3.
Images & figures
Original Euangelion chart of Xaira's XA-1 counts. Shared zero-to-182 scale; nested groups must not be added. Binding measurements do not establish patient benefit.
Xaira · XA-1 laboratory counts, October 2